FDA Commissioner Dr. Scott Gottlieb Promises CBD Regulation Discussions in April, Announces Resignation
The cannabis sector received a noteworthy bump in value after FDA Commissioner Dr. Scott Gottlieb confirmed that CBD talks will take place in April of this year. Commissioner Gottlieb addressed that there will be dialogue from relevant cannabis industry parties at the public hearing.
However, Dr. Gottlieb announced his resignation yesterday in a letter to his staff. Advocates are hopeful that Dr. Gottlieb’s departure will not hinder any progress towards new CBD rules and industry standards.
The hearing, should it still take place, will focus on the best way to proceed on cannabidiol (CBD) derived from hemp after the 2018 Farm Bill legalized hemp last year in December. CBD, the non-psychoactive ingredient in cannabis and hemp, wasn’t included within the bill that legalized hemp due to the small amount of research that was previously conducted on its long-term health effects.
Gottlieb stated: “We’re planning to seek broad public input on this pathway, including information on the science and safety behind CBD. But we know that this process could take time. So we’re also interested in hearing from stakeholders and talking to Congress on possible alternative approaches to make sure that we have an appropriately efficient and predictable regulatory framework for regulating CBD products.”
The Commissioner added that a framework to regulate high concentrate CBD as a pharmaceutical product and low concentrate CBD as a food or dietary supplement would “preserve the incentive to study CBD as a pharmaceutical product”.
Curious about how you can make money investing in cannabis? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.
Tags: Politics
FDA Commissioner Dr. Scott Gottlieb Promises CBD Regulation Discussions in April, Announces Resignation
About Cannin Investment Group: Your Pot Stocks Experts
Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020.
Use Cannin as your resource for:
- Cannabis and hemp investing news
- Featured cannabis and hemp company analysis
- Comprehensive cannabis and hemp stock reports
Is it too late to invest in pot stocks? No! This is the perfect time to invest.
Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.
Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?
Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.
- +25% Gains in 2020
- +49.8% Gains in 2019
- 108% Backtested since 2012
We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best pot stocks – we’ll show you how at cannin.com.
Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Penny Hemp Stocks